

- 2 -

Drewe *et al.*
Appl. No. 09/705,840.

However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

*Amendments**In the Claims:*

Please add the following new claims:

90. (New) The method of claim 27, wherein said compound is selected from the group consisting of:

2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(2-bromo-4,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-8-methyl-4H-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4H-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(3-nitrophenyl)-4H-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(3-cyanophenyl)-4H-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(3,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran; and

- 3 -

Drewe *et al.*
Appl. No. 09/705,840.

9-Acetamide-2-amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran.

91. (New) The method of claim 33, wherein said compound is selected from the group consisting of carboplatin, vinblastine, paclitaxel, cis-platin and 5-fluorouracil.

92. (New) The compound of claim 75 or 78, wherein said compound is a (+) enantiomer.

93. (New) The compound of claim 75 or 78, wherein said compound is a (-) enantiomer.